Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma

Yilmaz, Insu; tutar, nuri; Türk, Murat; nazik bahçecioğlu, sakine; ÇETİN, gülden; arslan, bahar

doi:10.3906/sag-2009-41

Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma

İnsu YILMAZ, (Erciyes Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İmmünoloji ve Allerji Anabilim Dalı, Kayseri, Türkiye)

Sakine BAHÇECİOĞLU, (Atatürk Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesi, İmmünoloji ve Allerji Anabilim Dalı, Ankara, Türkiye)

Murat TÜRK, (Kayseri İl Eğitim ve Araştırma Hastanesi, İmmünoloji ve Allerji Anabilim Dalı, Kayseri, Türkiye)

Nuri TUTAR, (Erciyes Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Kayseri, Türkiye)

Gülden PAÇACI ÇETİN, (Erciyes Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İmmünoloji ve Allerji Anabilim Dalı, Kayseri, Türkiye)

Bahar ARSLAN (Erciyes Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İmmünoloji ve Allerji Anabilim Dalı, Kayseri, Türkiye)

Turkish Journal of Medical Sciences

11 5

Yıl: 2021 Cilt: 51 Sayı: 4 Sayfa Aralığı: 1953 - 1959 Metin Dili: İngilizce DOI: 10.3906/sag-2009-41 İndeks Tarihi: 13-01-2022

Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma

Öz:

Background/aim: The efficacy of mepolizumab has been largely demonstrated in clinical trials in patients with severe eosinophilic asthma (SEA). However, reports on experience with mepolizumab in a real-life cohort are limited. Moreover, data about the effectiveness of mepolizumab on small airways is scarce. This study evaluated the effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, blood eosinophils, steroid dependence, and small airways in a real-life cohort of patients with SEA. Materials and methods: We retrospectively analyzed patients with SEA who were receiving fixed-dose mepolizumab. The effects of mepolizumab on clinical, laboratory, functional parameters were evaluated at 12th, 24th, and 52nd weeks. Small airways were assessed with the FEF 25-75. Results: A total of 41 patients were enrolled in the study. Mepolizumab significantly reduced asthma exacerbation rates, reduced mOCS dose, and improved asthma control test (ACT) scores at 12th, 24th, and 52nd weeks. However, we found no significant changes in FEV1 and FEF25-75 values at baseline, 12th, 24th, and 52nd weeks (78.9 ± 23.3%, 82.9 ± 23.4%, 81.9 ± 23.9%, and 78.9 ± 23.5% for FEV1; 45.1 ± 23.1%, 48.8 ± 23.5%, 48.7 ± 23.1%, and 41.0 ± 20.1% for FEF25-75, respectively) Conclusion: In this study, mepolizumab significantly improved all outcomes (symptom scores, asthma exacerbations, OCS sparing, and blood eosinophils) except functional parameters. Still, despite the dose reduction in mOCS dosage, no significant deterioration was observed in FEV1and FEF25-75 values.Key words: Mepolizumab, severe eosinophilic asthma, small airways, pulmonary function, asthma control test, oral corticosteroids

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Carr TF, Zeki AA, Monica Kraft M. Eosinophilic and noneosinophilic asthma. American Journal of Respiratory and Critical Care Medicine 2018; 197 (1): 22-37. doi: 10.1164/ rccm.201611-2232PP
2. Stirling RG, Van Rensen EI, Barnes PJ, Chung KF. Interleukin-5 induces CD34+ eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. American Journal of Respiratory and Critical Care Medicine 2001; 164 (8 Pt 1): 1403-1409. doi: 10.1164/ajrccm.164.8.2010002
3. Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nature Reviews Drug Discovery 2013; 12 (2): 117-129. doi: 10.1038/nrd3838
4. Walsh GM. Mepolizumab-based therapy in asthma: an update. Current Opinion in Allergy and Clinical Immunology 2015; 15 (4): 392-396. doi: 10.1097/ACI.0000000000000183
5. Fainardi V, Pisi G, Chetta A. Mepolizumab in the treatment of severe eosinophilic asthma. Immunotherapy 2016; 8 (1): 27-34. doi: 10.2217/imt.15.102
6. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England Journal of Medicine 2014; 371 (13): 1198-1207. doi: 10.1056/NEJMoa1403290
7. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380 (9842): 651-659. doi: 10.1016/S0140- 6736(12)60988-X
8. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. New England Journal of Medicine 2014; 371 (13): 1189-1197. doi: 10.1056/NEJMoa1403291
9. Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clinical Therapeutics 2016; 38 (9): 2058-2070. doi:
10.1016/j.clinthera.2016.07.010 10. Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME et al. The minimally important difference of the asthma control test. Journal of Allergy and Clinical Immunology 2009; 124 (4): 719-723. doi: 10.1016/j.jaci.2009.06.053
11. Meltzer EO, Hamilos DL. Rhinosinusitis diagnosis and management for the clinician: a synopsis of recent consensus guidelines. Mayo Clinic Proceedings 2011; 86 (5): 427-443. doi: 10.4065/mcp.2010.0392
12. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I et al. EPOS 2012; European position paper on rhinosinusitis and nasal polyps. A summary for otorhinolaryngologists. Rhinology 2012; 50 (1): 1-12. doi: 10.4193/Rhino50E2
13. Pelaia C, Busceti MT, Solinas S, Terracciano R, Pelaia G. Reallife evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: results of a single-centre observational study. Pulmonary Pharmacology and Therapeutics 2018; 53: 1-5. doi: 10.1016/j.pupt.2018.09.006
14. Kavanagh JE, Grainne d’Ancona M, Elstad M, Green L, Fernandes M et al. Real-world effectiveness and the characteristics of a “super-responder” to mepolizumab in severe eosinophilic asthma. Chest 2020; 158 (2): 491-500. doi: 10.1016/j.chest.2020.03.042
15. Yılmaz İ, Türk M, Nazik Bahçecioğlu S, Tutar N, Gülmez İ. Efficacy of mepolizumab treatment in oral corticosteroiddependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study. Turkish Journal of Medical Science 2020; 50 (2): 433-441. doi: 10.3906/sag-1912-62
16. Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. American Journal of Respiratory and Critical Care Medicine 2007; 176 (11): 1062- 1071. doi: 10.1164/rccm.200701-085OC
17. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Connor BJ et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356 (9248): 2144-2148. doi: 10.1016/s0140-6736(00)03496-6
18. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. American Journal of Respiratory and Critical Care Medicine 2003; 167 (2): 199-204. doi: 10.1164/rccm.200208-789OC
19. Siroux V, Boudier A, Dolgopoloff M, Chanoine S, Bousquet J et al. Forced midexpiratory flow between 25% and 75% of forced vital capacity is associated with long-term persistence of asthma and poor asthma outcomes. Journal of Allergy and Clinical Immunology 2016; 137 (6): 1709-1716. doi: 10.1016/j. jaci.2015.10.029
20. Parker AL, McCool FD. Pulmonary function characteristics in patients with different patterns of methacholine airway hyper responsiveness. Chest 2002; 121 (6): 1818-1823. doi: 10.1378/ chest.121.6.1818
21. Simon MR, Chinchilli VM, Phillips BR, Sorkness CA, Lemanske RF Jr et al. Forced expiratory flow between 25% and 75% of vital capacity and FEV1/forced vital capacity ratio in relation to clinical and physiological parameters in asthmatic children with normal FEV1 values. Journal of Allergy and Clinical Immunology 2010; 126 (3): 527-534. doi: 10.1016/j. jaci.2010.05.016
22. Farah CS, Badal T, Reed N, Rogers PG, King GG et al. Mepolizumab improves small airway function in severe eosinophilic asthma. Respiratory Medicine 2019; 148: 49-53. doi: 10.1016/j.rmed.2019.01.016
23. Singer F, Abbas C, Yammine S, Casaulta C, Frey U et al. Abnormal small airways function in children with mild asthma. Chest 2014; 145 (3): 492-499. doi: 10.1378/chest.13-0784
24. Robinson PD, Latzin P, Verbanck S, Hall GL, Horsley A et al. Consensus statement for inert gas washout measurement using multiple- and single- breath tests. The European Respiratory Journal 2013; 41 (3): 507-522. doi: 10.1183/09031936.00069712
25. Sposato B, Camiciottoli G, Bacci E, Scalese M, Carpagnano GE et al. Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life. Pulmonary Pharmacology and Therapeutics 2020; 61: 101899. doi: 10.1016/j.pupt.2020.101899
26. Riley CM, Wenzel SE, Castro M, Erzurum SC, Chung KF et al. Clinical implications of having reduced mid forced expiratory flow rates (FEF25-75), independently of FEV1, in adult patients with asthma. PloS One 2015; 10 (12): e0145476. doi: 10.1371/ journal.pone.0145476
27. Sutherland ER, Martin RJ, Bowler RP, Zhang Y, Rex MD et al. Physiologic correlates of distal lung inflammation in asthma. The Journal of Allergy and Clinical Immunology 2004; 113 (6): 1046-1050. doi: 10.1016/j.jaci.2004.03.016
28. Konstantinos Katsoulis K, Kostikas K, Kontakiotis T. Techniques for assessing small airways function: possible applications in asthma and COPD. Respiratory Medicine 2016; 119: e2-e9. doi: 10.1016/j.rmed.2013.05.003

APA	Yilmaz I, nazik bahçecioğlu s, Türk M, tutar n, ÇETİN g, arslan b (2021). Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma. , 1953 - 1959. 10.3906/sag-2009-41
Chicago	Yilmaz Insu,nazik bahçecioğlu sakine,Türk Murat,tutar nuri,ÇETİN gülden,arslan bahar Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma. (2021): 1953 - 1959. 10.3906/sag-2009-41
MLA	Yilmaz Insu,nazik bahçecioğlu sakine,Türk Murat,tutar nuri,ÇETİN gülden,arslan bahar Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma. , 2021, ss.1953 - 1959. 10.3906/sag-2009-41
AMA	Yilmaz I,nazik bahçecioğlu s,Türk M,tutar n,ÇETİN g,arslan b Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma. . 2021; 1953 - 1959. 10.3906/sag-2009-41
Vancouver	Yilmaz I,nazik bahçecioğlu s,Türk M,tutar n,ÇETİN g,arslan b Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma. . 2021; 1953 - 1959. 10.3906/sag-2009-41
IEEE	Yilmaz I,nazik bahçecioğlu s,Türk M,tutar n,ÇETİN g,arslan b "Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma." , ss.1953 - 1959, 2021. 10.3906/sag-2009-41
ISNAD	Yilmaz, Insu vd. "Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma". (2021), 1953-1959. https://doi.org/10.3906/sag-2009-41

APA	Yilmaz I, nazik bahçecioğlu s, Türk M, tutar n, ÇETİN g, arslan b (2021). Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma. Turkish Journal of Medical Sciences, 51(4), 1953 - 1959. 10.3906/sag-2009-41
Chicago	Yilmaz Insu,nazik bahçecioğlu sakine,Türk Murat,tutar nuri,ÇETİN gülden,arslan bahar Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma. Turkish Journal of Medical Sciences 51, no.4 (2021): 1953 - 1959. 10.3906/sag-2009-41
MLA	Yilmaz Insu,nazik bahçecioğlu sakine,Türk Murat,tutar nuri,ÇETİN gülden,arslan bahar Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma. Turkish Journal of Medical Sciences, vol.51, no.4, 2021, ss.1953 - 1959. 10.3906/sag-2009-41
AMA	Yilmaz I,nazik bahçecioğlu s,Türk M,tutar n,ÇETİN g,arslan b Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma. Turkish Journal of Medical Sciences. 2021; 51(4): 1953 - 1959. 10.3906/sag-2009-41
Vancouver	Yilmaz I,nazik bahçecioğlu s,Türk M,tutar n,ÇETİN g,arslan b Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma. Turkish Journal of Medical Sciences. 2021; 51(4): 1953 - 1959. 10.3906/sag-2009-41
IEEE	Yilmaz I,nazik bahçecioğlu s,Türk M,tutar n,ÇETİN g,arslan b "Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma." Turkish Journal of Medical Sciences, 51, ss.1953 - 1959, 2021. 10.3906/sag-2009-41
ISNAD	Yilmaz, Insu vd. "Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma". Turkish Journal of Medical Sciences 51/4 (2021), 1953-1959. https://doi.org/10.3906/sag-2009-41